Clinical Comparison of Docetaxel/ Oxal iplatin/ Capecitabine and Folfox 4 in Treating Advanced Gastric Cancer

Objective 　To evaluate the objective response rate, time to progression ( TTP) and toxicity between Docetaxel/ Oxaliplatin/ Capecitabine and Folfox 4 in the t reatment for the advanced gastric cancer. Methods 　Forty-one patients with advanced gastric cancer were administ rated with Docetaxel 25 mg/ m² (d1, d8, d15), Oxaliplatin 60 mg/ m² (d1, d8, d15), and Capecitabine 1 250 mg/ m² / d divided in two daily doses given from d1 to d14 . The cycles were repeated every 28 days. All patient s received two to six cycles. The other 40 patients with advanced gast ric cancer were administ rated with Oxaliplatin (85 mg/ m², ivgtt, d1) combined with Leucovorin (200 mg/ m², ivgtt ; d1 to d2), Fluorouraci1 ( 400 mg/ m², iv, followed by 5-Fu 600 mg/ m² continuous venous infusion 22 hours, dl to d2), repeated every 14 days, twice for one recycle. The t reatment was finished after 2 recycles. Results 　The outcomes the regimen was as follows : The total response rate in Docetaxel/ Oxaliplatin/ Capecitabine was 51. 6 %, The most common adverse effects were leucopenia, neut ropenia, hand foot syndrome and peripheral neuropathy. The response rate in Folfox4 was 47. 4 %, The most common adverse effect s were leucopenia, neut ropenia, and peripheral neuropathy. The median TTP of primary and secondary treatment were 6. 8 months and 5. 9 months respectively. Conclusion 　The Docetaxel/ Oxaliplatin/ Capecitabine regimen offers a better therapeutic option in patients with advanced gastric cancer.